PLAT, plasminogen activator, tissue type, 5327

N. diseases: 392; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2676721
Disease: Thrombophilia, Familial, Due To Decreased Release Of Tissue Plasminogen Activator
Thrombophilia, Familial, Due To Decreased Release Of Tissue Plasminogen Activator 		0.500 Biomarker disease GENOMICS_ENGLAND
CUI: C2676721
Disease: Thrombophilia, Familial, Due To Decreased Release Of Tissue Plasminogen Activator
Thrombophilia, Familial, Due To Decreased Release Of Tissue Plasminogen Activator 		0.500 Biomarker disease CTD_human
CUI: C2676721
Disease: Thrombophilia, Familial, Due To Decreased Release Of Tissue Plasminogen Activator
Thrombophilia, Familial, Due To Decreased Release Of Tissue Plasminogen Activator 		0.500 Biomarker disease GENOMICS_ENGLAND
CUI: C0398623
Disease: Thrombophilia
Thrombophilia 		0.100 Biomarker disease HPO
CUI: C1735901
Disease: Recurrent deep vein thrombosis
Recurrent deep vein thrombosis 		0.100 Biomarker phenotype HPO
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 GeneticVariation group BEFREE We have demonstrated that ACR cells can be differentially transformed by oncogenic viruses, a carcinogen (MNNG), and gamma-ray irradiation, and that they can proliferate in vitro after exposure to a tumor promoter (TPA. 7046911 1982
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE We speculated that TPA-induced aneuploidy in these cells, coupled with DNA instability and aberrant chromosomal segregation, may conceivably be consistent with neoplasia in initiated ACR cells. 7066921 1982
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.090 Biomarker group BEFREE We further suggest that, through the use of TPA, various stages associated with cancer development in humans, i.e., initiation through promotion and progression, can be identified in vitro. 7046911 1982
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE We further suggest that, through the use of TPA, various stages associated with cancer development in humans, i.e., initiation through promotion and progression, can be identified in vitro. 7046911 1982
CUI: C0008626
Disease: Congenital chromosomal disease
Congenital chromosomal disease 		0.050 Biomarker group BEFREE Chromosome abnormalities in chronic lymphocytic leukemia revealed by TPA as a mitogen. 6883302 1983
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.030 Biomarker disease BEFREE Chromosome abnormalities in chronic lymphocytic leukemia revealed by TPA as a mitogen. 6883302 1983
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.010 AlteredExpression disease BEFREE Immunoglobulin heavy chain gene rearrangement was evaluated in 19 cases of acute lymphoblastic leukemia (ALL) and correlated with the immunological phenotypic expression on primary or phorbol diester (12-O-tetradecanoylphorbol-13-acetate [TPA])-induced cells. 6438157 1984
CUI: C0023452
Disease: Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia 		0.010 AlteredExpression disease BEFREE Immunoglobulin heavy chain gene rearrangement was evaluated in 19 cases of acute lymphoblastic leukemia (ALL) and correlated with the immunological phenotypic expression on primary or phorbol diester (12-O-tetradecanoylphorbol-13-acetate [TPA])-induced cells. 6438157 1984
CUI: C0751606
Disease: Adult Acute Lymphocytic Leukemia
Adult Acute Lymphocytic Leukemia 		0.010 AlteredExpression disease BEFREE Immunoglobulin heavy chain gene rearrangement was evaluated in 19 cases of acute lymphoblastic leukemia (ALL) and correlated with the immunological phenotypic expression on primary or phorbol diester (12-O-tetradecanoylphorbol-13-acetate [TPA])-induced cells. 6438157 1984
CUI: C1292769
Disease: Precursor B-cell lymphoblastic leukemia
Precursor B-cell lymphoblastic leukemia 		0.010 AlteredExpression disease BEFREE The only cALL case that was not rearranged expressed no B cell markers either on primary or on TPA-induced cells. 6438157 1984
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 GeneticVariation group BEFREE The effects of the carcinogens (4NQO, 4-nitroquinoline-N-oxide; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; AFLG1, aflatoxin G1; AFLB1, aflatoxin B1; BNU, butylnitrosourea; MNU, methylnitrosourea) and the tumor promoter (TPA, 12-O-tetradecanoylphorbol-13-acetate) on sister chromatid exchanges (SCE), chromosome aberrations and colony formation (CF) were examined in three types of Bloom syndrome (BS) B-lymphoblastoid cell lines (B-LCLs); type I with normal SCE and normal karyotype; type II with high SCE and normal karyotypes; type III with high SCE and abnormal karyotypes. 3876929 1985
CUI: C0008626
Disease: Congenital chromosomal disease
Congenital chromosomal disease 		0.050 GeneticVariation group BEFREE The effects of the carcinogens (4NQO, 4-nitroquinoline-N-oxide; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; AFLG1, aflatoxin G1; AFLB1, aflatoxin B1; BNU, butylnitrosourea; MNU, methylnitrosourea) and the tumor promoter (TPA, 12-O-tetradecanoylphorbol-13-acetate) on sister chromatid exchanges (SCE), chromosome aberrations and colony formation (CF) were examined in three types of Bloom syndrome (BS) B-lymphoblastoid cell lines (B-LCLs); type I with normal SCE and normal karyotype; type II with high SCE and normal karyotypes; type III with high SCE and abnormal karyotypes. 3876929 1985
CUI: C0005859
Disease: Bloom Syndrome
Bloom Syndrome 		0.010 GeneticVariation disease BEFREE The effects of the carcinogens (4NQO, 4-nitroquinoline-N-oxide; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; AFLG1, aflatoxin G1; AFLB1, aflatoxin B1; BNU, butylnitrosourea; MNU, methylnitrosourea) and the tumor promoter (TPA, 12-O-tetradecanoylphorbol-13-acetate) on sister chromatid exchanges (SCE), chromosome aberrations and colony formation (CF) were examined in three types of Bloom syndrome (BS) B-lymphoblastoid cell lines (B-LCLs); type I with normal SCE and normal karyotype; type II with high SCE and normal karyotypes; type III with high SCE and abnormal karyotypes. 3876929 1985
CUI: C0019243
Disease: Angioedemas, Hereditary
Angioedemas, Hereditary 		0.010 Biomarker disease BEFREE Since C1-inhibitor, the deficient protein in HAE, is a poor inhibitor of the well-known extrinsic (tissue-type) plasminogen activator, but the major inhibitor of the contact activation system and a related in vitro phenomenon termed intrinsic fibrinolysis, our data show that this fibrinolytic system is also sometimes operating efficiently in vivo. 2935973 1985
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.400 Therapeutic disease CTD_human Safety of helicopter transport and out-of-hospital intravenous fibrinolytic therapy in patients with evolving myocardial infarction. 3089627 1986
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Finally, transcription of c-fos in A431 cells is markedly induced by the tumor promoter TPA and the calcium ionophore A23187, yet neither induced an increased level of the enhancer-binding activity. 3096578 1986
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.010 GeneticVariation group BEFREE The t-PA gene localization coincides with a translocation breakpoint observed in myeloproliferative disorders. 3092643 1986
CUI: C1292778
Disease: Chronic myeloproliferative disorder
Chronic myeloproliferative disorder 		0.010 Biomarker disease BEFREE Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder. 3092643 1986
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.400 Therapeutic disease CTD_human Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up. 3121335 1987
CUI: C0524702
Disease: Pulmonary Thromboembolisms
Pulmonary Thromboembolisms 		0.310 Biomarker disease CTD_human Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy. 3105914 1987